Loading clinical trials...
Loading clinical trials...
A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Conditions
Interventions
RBN-2397
Locations
15
United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
SCRI-Denver/HealthOne
Denver, Colorado, United States
Yale Cancer Center, Yale University
New Haven, Connecticut, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, United States
SCRI-Sarasota/Florida Cancer Specialists
Sarasota, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
August 1, 2019
Primary Completion Date
June 30, 2023
Completion Date
July 31, 2023
Last Updated
March 28, 2023
NCT05223608
NCT06625775
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
Ribon Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions